Picture of Nexentis Technologies logo

NXTS Nexentis Technologies Share Price

0.000.00%
us flag iconLast trade - 00:00
Basic MaterialsSpeculativeMicro CapValue Trap

Momentum

Relative Strength (%)
1m+27.05%
3m-35.78%
6m-77.3%
1yr-95.8%
Volume Change (%)
10d/3m-60.55%
Price vs... (%)
52w High-95.31%
50d MA+0.93%
200d MA-77.49%

Growth & Value

Shareholder Activity

TypeBuy / Hold / Sell
Institutions
Directors
Community

Guru Screens

Quality

NameIndustryMarket
Return on Capital-22.3%
Return on Equity-33.17%
Operating Marginn/a

Health Trend(F-Score)

12345678910

Bankruptcy Score(Z-Score)

Distress
Cautious
Safe

Earnings Manipulation Risk(M-Score)

Other Ratios

Leverage (ttm)Total- Intang+ Pension
Gross Gearing
Net Gearing
Cash / Assets

Recent History

Latest interim period vs. prior periodIndustryMarket
Sales Growth
EPS Growth
3yr Compound Annual Growth RateIndustryMarket
Sales CAGR
EPS CAGR
DPS CAGR

Graphical History

Revenue
Blurred out image of Revenue chart
Net Income
Blurred out image of Net Income chart
Normalised EPS
Blurred out image of Normalised EPS chart
PE Ratio Range
Blurred out image of PE Ratio Range chart
Dividend Yield Range
Blurred out image of Dividend Yield Range chart

Analyst Forecasts

Price target
( price)
31st Dec 202631st Dec 2027
Est. Long Term Growth Rate: Net Profit
()
EPS
()
DPS
()
Net Profit
()
EPS
()
DPS
()
Consensus Estimate
1m Change
3m Change

Analyst Consensus

Strong SellSellHoldBuyStrong Buy

EPS 2026 / 2027

Blurred out image of Nexentis Technologies EPS forecast chart

Profile Summary

Nexentis Technologies Inc, formerly known as N2OFF, Inc., is an AI and data-driven computational biotech platform focused on mitochondrial biology, precision oncology and inflammatory metabolic diseases. Through its subsidiary MitoCareX Bio Ltd. The company uses a proprietary discovery engine targeting the mitochondrial SLC25 carrier family using its MITOLINE algorithm and structure guided virtual screening workflows. MITOLINE, its proprietary computational platform, is designed to allow proper homology modeling of mitochondrial membrane proteins, particularly transport proteins. It enables three-dimensional structural modeling and large-scale virtual screening, MITOLINE opens access to a novel untapped target space, allowing the Company to identify small-molecule modulators that directly disrupt cancer metabolism with the potential of minimizing systemic toxicity.

Directors

Last Annual
December 31st, 2025
Last Interim
December 31st, 2025
Incorporated
November 3rd, 2023
Public Since
May 26th, 2010
No. of Shareholders
183
No. of Employees
7
Sector
Chemicals
Industry
Basic Materials
Exchange
us flag iconNASDAQ Capital Market
Shares in Issue
730,309

NXTS Share Price Performance

Upcoming Events for NXTS

Similar to NXTS

Picture of CN ENERGY logo

CN ENERGY

us flag iconNASDAQ Capital Market

Picture of EUPEC International logo

EUPEC International

us flag iconNASDAQ Capital Market

Picture of Gulf Resources logo

Gulf Resources

us flag iconNASDAQ Capital Market

Picture of Origin Materials logo

Origin Materials

us flag iconNASDAQ Capital Market

Picture of SenesTech logo

SenesTech

us flag iconNASDAQ Capital Market

FAQ